Labiotech.eu

News and Trends 30 Jun 2017

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the market, the company has closed a Series C round with $45M (€39.5M) […]

June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Inside Labiotech 30 Jun 2017

Infographic: Labiotech’s Story in a Line 😉

We will keep growing and having fun for many years! When we look back, we can proudly see how much we have achieved during these years. Today, we are excited to share with all our storyline, with the most special moments. Some of you know us from the beginning (hi dad and mom), but many only know […]

June 30, 2017 - 1 minutemin - By Editorial Team

More News! 30 Jun 2017

Fig Enzyme could Help to fight Infection and Heal Wounds

Russian researchers have investigated the properties of ficin, an enzyme that breaks down proteins, in helping antibiotics be more effective against infections like Staphylococcus. At Kazan Federal University and Voronezh University, in Russia, researchers are turning their attention to an understudied protease extracted from fig’s latex. As now published in Scientific Reports, the enzyme turned out to […]

June 30, 2017 - 2 minutesmins - By Denise Neves Gameiro

Startup Scout 30 Jun 2017

This Danish Biotech Thinks it Can Tackle the Obesity Epidemic

Apart from boasting big players in the space of metabolic diseases including Novo Nordisk and Zealand Pharma, Copenhagen is a hotspot for research on obesity and diabetes. This week we had a look at Copenhagen’s latest addition to the field, Antag Therapeutics. Mission: Antag Therapeutics is working on new treatments for the growing number of patients with obesity. […]

June 30, 2017 - 2 minutesmins - By Melanie De Almeida

servier transgene car t cells viral vector

News and Trends 29 Jun 2017

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to enter the promising CAR-T field in 2015, when it acquired the rights to UCART19 from Cellectis. The therapy, currently in Phase I, has already saved two babies […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Jun 2017

This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis

Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment in another Phase II study for PBC. Genkyotex is not giving up after its lead candidate, GKT831, failed to meet the primary endpoint in a Phase II trial in patients with type 2 diabetes and kidney disease. The French biotech has […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Jun 2017

New Drug for Neuropathic Pain Is Forging its Way through the Clinic

Pharmaleads has scored positive results in a first Phase I trial for its DENKI peptide PL265 to treat chronic neuropathic pain. The treatment of neuropathic pain commonly involves the prescription of opioids, anti-depressants or anti-convulsants, despite limited efficacy and marked side-effects of these drugs. Paris-based Pharmaleads is exploring new pathways to treat pain based on so-called DENKI peptides […]

June 29, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 29 Jun 2017

Video: Questions about Biotech Capital Markets? Kempen & Co have Answers

In our first Refresh expert track presentation the audience had the chance to learn about the life sciences capital market, ask questions they had never dared to ask and discover the top five facts on the life sciences capital markets! With its strong focus on the life sciences and healthcare industry, the investment bank Kempen & […]

June 29, 2017 - 2 minutesmins - By External Contributor

News and Trends 28 Jun 2017

Swiss Scientists Have Designed New Proteins to Treat Muscular Dystrophy

Researchers at the University of Basel have designed two proteins that can reverse congenital muscular dystrophy and increase the lifespan of mice. Congenital muscular dystrophy (CMD) englobes several genetic diseases that cause muscle weakness from birth. As patients age, the disease becomes more severe and affects breathing, often leading to death before adulthood. Unfortunately, there […]

June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Jun 2017

A Peek into the Icelandic Company using Fish Skin to Heal Wounds

Kerecis exploits the natural properties of fish skin to manufacture wound dressings that help tissues repair much faster than before. From a small town in northern Iceland, Kerecis is revolutionizing the treatment of wounds with a local product, fish. The company has developed a method to turn their skin into wound dressings that promote cell growth […]

June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 28 Jun 2017

Video: The Next Big Thing in Biotech according to Sofinnova’s Antoine Papiernik

Antoine Papiernik, Managing Partner at the famous European biotech VC Sofinnova, closed Refresh this year with a keynote on the next big thing in biotech. Papiernik has more than 20 years of experience as a VC investor and has helped build major European biotechs like Actelion, ProQR or Movetis. Being part of the leading edge […]

June 28, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 28 Jun 2017

Danish Biotech Reports Positive Phase II data for a Common Cold Vaccine

Bavarian Nordic has announced positive Phase II results for its universal vaccine against the common cold virus, RSV, which can be deadly for the elderly. The respiratory syncytial virus (RSV) is one of the perpetrators behind the common cold. For most, the virus just leads to a few uncomfortable days or weeks. But for children […]

June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

Infographic: Labiotech’s Story in a Line 😉

Fig Enzyme could Help to fight Infection and Heal Wounds

This Danish Biotech Thinks it Can Tackle the Obesity Epidemic

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis

New Drug for Neuropathic Pain Is Forging its Way through the Clinic

Video: Questions about Biotech Capital Markets? Kempen & Co have Answers

Swiss Scientists Have Designed New Proteins to Treat Muscular Dystrophy

A Peek into the Icelandic Company using Fish Skin to Heal Wounds

Video: The Next Big Thing in Biotech according to Sofinnova’s Antoine Papiernik

Danish Biotech Reports Positive Phase II data for a Common Cold Vaccine

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!